HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer

HER2 aberrations have been reported as a novel biomarker in HER2-directed therapy or as a prognostic marker in various tumor types. However, in advanced biliary tract cancer (BTC), there have been few studies regarding HER2 aberrations as a biomarker. We analyzed 121 advanced BTC patients who had be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hongsik, Kim, Ryul, Kim, Hye Ryeon, Jo, Hyunji, Kim, Hana, Ha, Sang Yun, Park, Joon Oh, Park, Young Suk, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896348/
https://www.ncbi.nlm.nih.gov/pubmed/35252005
http://dx.doi.org/10.3389/fonc.2022.834104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896348/
https://www.ncbi.nlm.nih.gov/pubmed/35252005
http://dx.doi.org/10.3389/fonc.2022.834104

Ejemplares similares